RESULTS	Landmark analysis suggested a benefit of TEVAR for all end points between 2 and 5 years ; for example , for all-cause mortality ( 0 % versus 16.9 % ; P = 0.0003 ) , aorta-specific mortality ( 0 % versus 16.9 % ; P = 0.0005 ) , and for progression ( 4.1 % versus 28.1 % ; P = 0.004 ) ; Landmarking at 1 year and 1 month revealed consistent findings .\